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were based on the 2013 utilisation volume data. Other local specific considerations 
e.g. subsidized selling prices and co-payments were included in the analyses for an 
assumed size of eligible patients. Sensitivity analyses were conducted. Results: 
The adoption rates of BIAsp were assumed to increase from 23.6% in 2013 to 30% 
or 36.5% in 2018 for base case and upside scenario, respectively. In comparison 
to base case scenario, increases in adoption rate of BIAsp were associated with a 
cumulative increase up to slightly greater than S$ 2.02M in insulin acquisition cost 
but a potential cumulative net saving up to approximately S$0.92M in overall total 
costs over 5 years, attributing to subsidized selling price of BIAsp assuming it is 
included standard drug list and its significantly lower major hypoglycaemia risk, 
respectively. Cost savings were predicted for other complications. ConClusions: 
The wider adoption of BIAsp was predicted to result in net cost savings from patient 
perspective in Singapore. More cost saving would be estimated in analyses with 
reduced productivity loss from a societal perspective.
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objeCtives: Patient-driven titration has been proven as efficacious and safe as physi-
cian-driven titration of Biphasic Insulin Aspart 30 (BIAsp 30) in people with type 2 dia-
betes (T2DM) in China in the 20-week trial (ClinicalTrials.gov identifier: NCT01618214). 
This study was to further compare titration-related health care utilizations and costs 
associated with BIAsp 30 self-driven versus physician-driven titration in China based 
on this trial. Methods: 344 eligible premixed/self-mixed human insulin users with 
T2DM were randomly assigned to BIAsp 30 twice daily either with self-driven or 
physician-driven titration. Mean number of self-measured plasma glucose (SMPG), 
clinical visits and phone contacts with health care practitioners (HCPs) due to insu-
lin-titration were recorded in the trial and used to evaluate health care utilization. 
Costs were calculated from a societal perspective, including: 1) direct medical costs, 
multiplying utilizations in the trial and unit cost reported in the literature; 2) direct 
non-medical costs as transportation fees from previous studies; and 3) indirect costs 
estimated by human capital approach. Results: During the 20-week trial period, 
health care utilization associated with self-driven titration was lower than that with 
physician-driven titration (mean number of SMPG was 147.15 versus 151.31(P= 0.5178), 
outpatient visits was 5.69 versus 8.86 (P< 0.001), calls was 5.94 versus 5.98 (P= 0.1956), 
and there were no titration-related hospitalizations in both groups). Average total 
titration-related costs were CNY 424.93 lower in self-driven group than in physician-
driven group (total cost was CNY 1654.14 versus CNY 2079.07; direct medical cost 
was CNY 1151.31 versus CNY 1329.06; transportation cost was CNY 360.61 versus 
CNY 537.88; and indirect cost was CNY 142.22 versus CNY 212.13). ConClusions: 
Self-driven titration of BIAsp 30 was associated with less health care utilization and 
lower costs compared to physician-driven titration in people with T2DM in China. 
The new evidence suggests that a more patient-focused approach towards diabetes 
management may be cost-saving and improve overall efficiency.
PDB17
eConomiC BUrDen of tyPe 2 DiaBetes mellitUs for Costa riCa
Soto Molina H1, Díaz Martínez JP2, RamírezRamírez  MA3, Escobar Juárez Y2, Pizarro 
Castellanos M4
1Universidad Autónoma Metropolitana, Mexico City, Mexico, 2HS Estudios Farmacoeconómicos, 
Mexico City, Mexico, 3Novo Nordisk CLAT, Mexico City, Mexico, 4Hospital Infantil Federico Gomez, 
Distrito Federal, Mexico
objeCtives: To perform a partial economic evaluation of Type 2 Diabetes 
Mellitus (DM2) as well as its micro and macrovascular complications from the 
institutional point of view. (Social Security Costarican Register (CCSR)), for the 
year 2013. Methods: A partial economic evaluation evaluation analysis was used 
to analyse the average annual cost for DM2 in costarrican patients. The analysis 
pays special attention related to the sickness (cardiovascular, renal, microvascular, 
ophthalmic complications and acute events). Costarrican literature was reviews 
to obtain costs for DM2 as for its complications, also clinical practice guides for 
the use of resources were used and finally, this information was validated with 
specialist physicians from Costa Rica. Only direct medical costs were used, such as: 
medications, laboratory and additional studies, medical consults, hospitalizations 
and material; these were obtained from the Cost Model 2013 of the CCSR such as 
the Statistical Annual Yearbook. To prove the strength of the analysis, deterministic 
and probabilistic sensitivity tests were performed. Results: The average annual 
cost for DM2 for the year 2013 in Costa Rica was USD $1,466.17. The macro and 
microvascular complications related to DM2 were more expensive in 2013 for Costa 
Rica were the following: USD $105,865.80 for haemodyalisis during the first year, USD 
$21,600.40 for chronic cardiac failure during the first year, USD $15,414.40 for acute 
myocardial infarction and USD $15,025.39 for amputation. An average, hospitaliza-
tions represented a 27% of the resources used for treatment of complications. The 
sensitivity analysis proved the strength of the costs. ConClusions: Despise the 
lack of information in the literature, this article is the first approximation of costs 
on DM2 and its complications in Costa Rica for the year 2013.
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Among 150 (14.5%) patients who died during hospitalization, 102(68.0%) patients 
have used HES. and 105 (70.0%) patients were males. Multivariate logistic regres-
sion suggested that patients who ever used HES were associated with higher risk 
of mortality (adjusted odds ratio, AOR: 1.60; 95%CI: 1.04-2.45) even after adjusting 
for IHD (AOR: 1.64; 95%CI: 0.98-2.74), CRF (AOR: 4.28; 95%CI: 2.35-7.79), high blood 
glucose (AOR: 2.85; 95%CI: 1.83-4.45), AKI during hospitalization (AOR: 4.30; 95%CI: 
2.79-6.62). ConClusions: Use of HES may be independently associated with higher 
risk of death in ICU patients with diabetes. However, further studies are required to 
demonstrate the causation of HES and hospitalized mortality.
DiaBetes/enDoCrine DisorDers – Cost studies
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objeCtives: Budget impact analysis (BIA) is a useful tool for reimbursement 
decision-makers in health technology assessments by authorities across different 
countries. This study aimed to evaluate the financial impact from the Ministry of 
Health (MOH) perspective of different adoption rates of Biphasic Insulin Aspart 
(BIAsp) versus Biphasic Human Insulin (BHI) in treating type 2 diabetes melli-
tus. Methods: An Excel based 5-year budget impact model was built to estimate 
insulin treated patients by public providers using local prevalence data. The pub-
lished demographic, efficacy and adverse event data for ASEAN subgroup analyses 
of A1chieve study was applied. Both insulin acquisition costs and other medical 
costs for complications e.g. major hypoglycaemia, myocardial infarction, stroke, 
end-stage renal disease, blindness and amputation were included at a discount rate 
of 3%. The incidence rates of these complications were derived from the established 
UKPDS equations. The adoption rates were assumed and projected from the 2013 
utilisation volume data of BIAsp and BHI by public providers. Sensitivity analyses 
were conducted. Results: The adoption rates of BIAsp were assumed to increase 
from 1.8% in 2013 to 4.5% or 6.9% in 2018 for base case and upside scenario, respec-
tively. Compared to the base case, upside scenario of wider BIAsp adoption was 
associated with an increased insulin cost up to RM 8.2M which was offset by avoided 
complication costs resulting in an overall net budget saving of approximately RM 
5.5M over 5 years, primarily driven by estimated reduction in major hypoglycae-
mia events for patients treated with BIAsp. ConClusions: The higher and wider 
adoption of BIAsp would likely be associated with cost savings in Malaysia from the 
MOH perspective attributed to its superiority in H1Ac reduction and lower major 
hypoglycemia risk in comparison to BHI. More cost saving would be concluded if 
productivity loss is included from a societal perspective.
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objeCtives: To estimate the budget impact of switching to U100 insulin (100 units 
[U]/ml) in Egyptian diabetic patients over a time horizon of 5 years. Methods: 
Pharmacy and medical budget impacts were estimated over the first 5 years of 
U100 insulin use in diabetic patients from the Egyptian health care system’s per-
spective. Local epidemiology data were used to estimate target population size. 
Pre-U100 insulin entry treatment option included U40 insulin (40 units [U]/ml). 
Pre- and post-U100 insulin entry market shares were estimated based on market 
research and assumptions. Direct medical costs were derived from the Ministry of 
Health tender list. All costs were reported in Egyptian pounds of the financial year 
2014. Deterministic sensitivity analysis was conducted. Results: In a hypotheti-
cal 85,294,388-member plan, 1,234,380 patients were expected to be candidates for 
U100 insulin treatment in type I and type II diabetes. The total budget impact after 
5 years post-U100 insulin was EGP -0.049 per member per month [PMPM] (pharmacy 
budget: EGP -0.047 PMPM; medical budget: EGP -0.002 PMPM), assuming 53.59% of the 
target population would switch to U100 insulin. Sensitivity analyses determined that 
the cost of U40 insulin and U100 insulin had the potential to impact the base case 
analysis. ConClusions: The total budget for diabetes following U100 insulin use 
were cost-saving in comparison to U40 insulin. Conversion to U100 insulin would 
result in lower overall treatment costs in patients with diabetes from the health 
care system’s perspective. An intensive information campaign providing detailed 
advice for patients, physicians and pharmacists is essential for the prevention of 
medication errors and reduction of overall costs.
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objeCtives: Economic evaluations of BIAsp have been published in the context 
of different countries. This study aimed to evaluate the financial impact from a 
perspective of patients treated by public providers of different adoption rates of 
Biphasic Insulin Aspart (BIAsp; NovoMix 30 FlexPen®) versus Biphasic Human 
Insulin (BHI; Mixtard Penfill®) in treating T2DM. Methods: An Excel based 5-year 
budget impact model was built to estimate insulin treated patients by public pro-
viders using the local prevalence data. The published demographic, efficacy and 
adverse event data for ASEAN subgroup analyses of A1chieve study was applied. 
Both insulin acquisition costs and medical costs for major hypoglycaemia and other 
complications were applied with a 3% discount rate to the estimated corresponding 
incidence rates derived from the UKPDS equations. The projected adoption rates 
